Neurology and Neurosurgery

Episodes 17-32 of 433

Individualizing gMG Treatment: Defining Success With Each Patient
Individualizing gMG Treatment: Defining Success With Each Patient
NeuroFrontiers
Individualizing gMG Treatment: Defining Success With Each Patient
- Omar Sinno, MD
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
CME/CE
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
1.00 credit
- Stephen Chrzanowski, MD, PhD
- Aravindhan Veerapandiyan, MD
1.00 credit
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
CME/CE
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
0.25 credits
- Christoph U. Correll, MD
- Jonathan M. Meyer
0.25 credits
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
CME/CE
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
0.50 credits
- Neelam Goyal, MD
- Christyn Edmundson, MD
0.50 credits
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
NeuroFrontiers
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
NeuroFrontiers
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
- Ryan Quigley
Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
Global Neurology Academy
Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
- Tirisham V. Gyang, MD
- Gates B. Colbert, MD
Prevention on the Horizon: Early Intervention and Risk Reduction in MS Care
Prevention on the Horizon: Early Intervention and Risk Reduction in MS Care
Global Neurology Academy
Prevention on the Horizon: Early Intervention and Risk Reduction in MS Care
- Vikram V. Bhise, MD
Evolving Diagnostic and Prognostic Strategies in Multiple Sclerosis Care
Evolving Diagnostic and Prognostic Strategies in Multiple Sclerosis Care
Global Neurology Academy
Evolving Diagnostic and Prognostic Strategies in Multiple Sclerosis Care
- Ashley Baker, MSN, PMHNP
- Jay Avasarala, MD, PhD
Genetic Testing in Pediatrics: Identifying Neurodevelopmental Disorders Early
Genetic Testing in Pediatrics: Identifying Neurodevelopmental Disorders Early
Clinician's Roundtable
Genetic Testing in Pediatrics: Identifying Neurodevelopmental Disorders Early
- Jennifer M. Kalish, MD, PhD, FAAP
Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
NeuroFrontiers
Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
- Sergio Baranzini, PhD
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
NeuroFrontiers
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
- Michael Levy, MD, PhD
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
NeuroFrontiers
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
- Le Hua, MD
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
NeuroFrontiers
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
- Ryan Quigley
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
NeuroFrontiers
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
Modern MS Management: Leveraging Technology to Support Brain Health
Modern MS Management: Leveraging Technology to Support Brain Health
Global Neurology Academy
Modern MS Management: Leveraging Technology to Support Brain Health
- Victoria Leavitt, PhD
- Gates B. Colbert, MD

2/7

Neurology and Neurosurgery

Episodes 17-32 of 433

NEED HELP?

Contact us

NEED HELP?

Contact us

Episodes 17-32 of 433

Title

Share on ReachMD